Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neopath (NPTH) -- Ignore unavailable to you. Want to Upgrade?

To: Karl who wrote (63)	11/25/1997 11:55:00 PM
From: Sigmund	Read Replies (1) \| Respond to of 178

It's been frustrating watching the price of NeoPath decline even though regulatory approval would appear to be probable in the relatively short term. Does somebody know something bad about the prospects? But when I look at some other stocks in the sector, CYTEC, Neuromedical, and Matritech, I see that it is a sector trend and in fact NeoPath is holding its value better than these other companies. Perhaps this is a positive sign.

To: Karl who wrote (63)	11/27/1997 5:06:00 PM
From: John Zwiener	Read Replies (1) \| Respond to of 178

Thanks for the article. I tried to reread it, but its gone now. Personally, I thought the article was encouraging and relatively objective, and well done. Many biotechs are under pressure and it may not let up till mid-December. It could hit 12, but 13 or 14 would be worth picking up more, if only for a trading opportunity. The tidbits I pick up seems to indicate to me that this company continues to make incremental improvements. I still think they are out front and the future of pap or thinprep screening is in this area. On a more definite note, I strongly believe that the thinprep CYTYC is proving itself and will replace the pap smear. In my opinion of course. For a long time now, my three favorates have been IGEN (up almost 300%), SEPR (up 230%), and CYTYC (up only 10% since I first got it). In my opinion, all remain WAY undervalued. Also like LGND, ISIP, and LDAKA (the last one is speculation, lgnd and isip are better speculations, especially lgnd). Also, I've noticed that the best biotechs have very little in the way of postings, except when there is new information. (Well, except for lgnd which has so many postings that I wonder if it's being manipulated, at least short term, Henry is ok)